Ivacaftor (VX-770)Potent CFTR potentiator CAS# 873054-44-5 |
2D Structure
- VX-661
Catalog No.:BCC1241
CAS No.:1152311-62-0
- IOWH-032
Catalog No.:BCC3922
CAS No.:1191252-49-9
- CFTRinh-172
Catalog No.:BCC4419
CAS No.:307510-92-5
- GlyH-101
Catalog No.:BCC4104
CAS No.:328541-79-3
- PTC124 (Ataluren)
Catalog No.:BCC3881
CAS No.:775304-57-9
- VX-809
Catalog No.:BCC3712
CAS No.:936727-05-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 873054-44-5 | SDF | Download SDF |
PubChem ID | 16220172 | Appearance | Powder |
Formula | C24H28N2O3 | M.Wt | 392.49 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | VX-770 | ||
Solubility | DMSO : 50 mg/mL (127.39 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide | ||
SMILES | CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C | ||
Standard InChIKey | PURKAOJPTOLRMP-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Ivacaftor (VX-770) is a potentiator of CFTR for G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively. | |||||
Targets | G551D-CFTR | F508del-CFTR | ||||
IC50 | 100 nM | 25 nM |
Ivacaftor (VX-770) Dilution Calculator
Ivacaftor (VX-770) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5478 mL | 12.7392 mL | 25.4784 mL | 50.9567 mL | 63.6959 mL |
5 mM | 0.5096 mL | 2.5478 mL | 5.0957 mL | 10.1913 mL | 12.7392 mL |
10 mM | 0.2548 mL | 1.2739 mL | 2.5478 mL | 5.0957 mL | 6.3696 mL |
50 mM | 0.051 mL | 0.2548 mL | 0.5096 mL | 1.0191 mL | 1.2739 mL |
100 mM | 0.0255 mL | 0.1274 mL | 0.2548 mL | 0.5096 mL | 0.637 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Ivacaftor (VX-770) is a potent and orally bioavailable small molecule potentiator of cystic fibrosis transmembrane conductance regulator (CFTR). Studies in both G551D- and F508del-CFTR expressing cells have shown VX-700 combined with forskolin, but not VX-700 alone, has significantly increased CFTR-mediated Cl-secretion. The EC50 values of VX-700 in G551D- and F508del-CFTR are 100 nM and 25 nM, respectively [1].
VX-770 has been reported to reduce ENaC-mediated Na+ absorption and increase the amount of fluid on the apical surface in human CF bronchial epithelia (HBE) carrying G551D/F508del [1]. VX-770 combined with OAG has been shown to increase G551D-CFTR activity and OAG-dependent Ca2+ influx and in Chinese hamster ovary (CHO) cells [2].
References:
1. Van Goor F1, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, Zhou J, McCartney J,Arumugam V, Decker C, Yang J, Young C, Olson ER, Wine JJ, Frizzell RA, Ashlock M, Negulescu P. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18825-30.
2. Vachel L1, Norez C, Becq F, Vandebrouck C. Effect of VX-770 (ivacaftor) and OAG on Ca2+ influx and CFTR activity in G551D and F508del-CFTR expressing cells. J Cyst Fibros. 2013 Dec;12(6):584-91
- 3,29-Dibenzoyl karounitriol
Catalog No.:BCN2717
CAS No.:873001-54-8
- 6-Aminouracil
Catalog No.:BCC8768
CAS No.:873-83-6
- 3-Methoxyoxohernandaline
Catalog No.:BCN8107
CAS No.:872729-34-5
- 1,2,3,10-Tetramethoxy-9-(2-hydroxy-4,5-dimethoxybenzyloxy)oxoaporphine
Catalog No.:BCN8120
CAS No.:872729-33-4
- Dabigatran etexilate mesylate
Catalog No.:BCC1511
CAS No.:872728-81-9
- MEDICA 16
Catalog No.:BCC7956
CAS No.:87272-20-6
- 7-Epi-5-eudesmene-1beta,11-diol
Catalog No.:BCN7701
CAS No.:87261-77-6
- Ro 3306
Catalog No.:BCC4007
CAS No.:872573-93-8
- BGJ398
Catalog No.:BCC1278
CAS No.:872511-34-7
- (+)-Noe's reagent
Catalog No.:BCC8377
CAS No.:87248-50-8
- Bijaponicaxanthone C
Catalog No.:BCN6884
CAS No.:872409-35-3
- NVP-QAV680
Catalog No.:BCC5508
CAS No.:872365-16-7
- Ganoderone A
Catalog No.:BCN2448
CAS No.:873061-79-1
- IKK-16 (IKK Inhibitor VII)
Catalog No.:BCC4555
CAS No.:873225-46-8
- AIM-100
Catalog No.:BCC1333
CAS No.:873305-35-2
- Ramipril
Catalog No.:BCC5012
CAS No.:87333-19-5
- 1,7-Dihydroxy-4-methoxyxanthone
Catalog No.:BCN7602
CAS No.:87339-76-2
- TC-P 262
Catalog No.:BCC6155
CAS No.:873398-67-5
- Fortuneine
Catalog No.:BCN6401
CAS No.:87340-25-8
- Triangularine
Catalog No.:BCN2051
CAS No.:87340-27-0
- PU-H71
Catalog No.:BCC1872
CAS No.:873436-91-0
- Lupeolic acid
Catalog No.:BCN6520
CAS No.:87355-32-6
- GDC-0152
Catalog No.:BCC2252
CAS No.:873652-48-3
- Demethylcarolignan E
Catalog No.:BCN7018
CAS No.:873694-46-3
Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator.[Pubmed:25441013]
J Med Chem. 2014 Dec 11;57(23):9776-95.
Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.
Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.[Pubmed:27413118]
Mol Pharmacol. 2016 Sep;90(3):275-85.
Cystic fibrosis (CF) is caused by loss-of-function mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene encoding a phosphorylation-activated but ATP-gated chloride channel. Previous studies suggested that VX-770 [ivacaftor, N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide], a CFTR potentiator now used in clinics, increases the open probability of CFTR by shifting the gating conformational changes to favor the open channel configuration. Recently the chloride channel blocker and CFTR potentiator 5-nitro-2-(3-phenylpropylamino) benzoate (NPPB) has been reported to enhance CFTR activity by a mechanism that exploits the ATP hydrolysis-driven, nonequilibrium gating mechanism unique to CFTR. Surprisingly however, NPPB increased the activity of nonhydrolytic G551D-CFTR, the third most common disease-associated mutation. Here, we further investigated the mechanism of NPPB's effects on CFTR gating by assessing its interaction with well-studied VX-770. Interestingly, once G551D-CFTR was maximally potentiated by VX-770, NPPB further increased its activity. However, quantitative analysis of this drug-drug interaction suggests that this pharmacologic synergism is not due to independent actions of NPPB and VX-770 on CFTR gating; instead, our data support a dependent mechanism involving two distinct binding sites. This latter idea is further supported by the observation that the locked-open time of a hydrolysis-deficient mutant K1250A was shortened by NPPB but prolonged by VX-770. In addition, the effectiveness of NPPB, but not of VX-770, was greatly diminished in a mutant whose second nucleotide-binding domain was completely removed. Interpreting these results under the framework of current understanding of CFTR gating not only reveals insights into the mechanism of action for different CFTR potentiators but also brings us one step forward to a more complete schematic for CFTR gating.
Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770).[Pubmed:28012258]
Hepatology. 2017 Feb;65(2):560-570.
ABCB4 (MDR3) is an adenosine triphosphate (ATP)-binding cassette (ABC) transporter expressed at the canalicular membrane of hepatocytes, where it mediates phosphatidylcholine (PC) secretion. Variations in the ABCB4 gene are responsible for several biliary diseases, including progressive familial intrahepatic cholestasis type 3 (PFIC3), a rare disease that can be lethal in the absence of liver transplantation. In this study, we investigated the effect and potential rescue of ABCB4 missense variations that reside in the highly conserved motifs of ABC transporters, involved in ATP binding. Five disease-causing variations in these motifs have been identified in ABCB4 (G535D, G536R, S1076C, S1176L, and G1178S), three of which are homologous to the gating mutations of cystic fibrosis transmembrane conductance regulator (CFTR or ABCC7; i.e., G551D, S1251N, and G1349D), that were previously shown to be function defective and corrected by ivacaftor (VX-770; Kalydeco), a clinically approved CFTR potentiator. Three-dimensional structural modeling predicted that all five ABCB4 variants would disrupt critical interactions in the binding of ATP and thereby impair ATP-induced nucleotide-binding domain dimerization and ABCB4 function. This prediction was confirmed by expression in cell models, which showed that the ABCB4 mutants were normally processed and targeted to the plasma membrane, whereas their PC secretion activity was dramatically decreased. As also hypothesized on the basis of molecular modeling, PC secretion activity of the mutants was rescued by the CFTR potentiator, Ivacaftor (VX-770). CONCLUSION: Disease-causing variations in the ATP-binding sites of ABCB4 cause defects in PC secretion, which can be rescued by ivacaftor. These results provide the first experimental evidence that ivacaftor is a potential therapy for selected patients who harbor mutations in the ATP-binding sites of ABCB4. (Hepatology 2017;65:560-570).
Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).[Pubmed:26492939]
Br J Pharmacol. 2016 Feb;173(3):459-70.
BACKGROUND AND PURPOSE: The most common cystic fibrosis (CF) mutation F508del inhibits the gating and surface expression of CFTR, a plasma membrane anion channel. Optimal pharmacotherapies will probably require both a 'potentiator' to increase channel open probability and a 'corrector' that improves folding and trafficking of the mutant protein and its stability at the cell surface. Interaction between CF drugs has been reported but remains poorly understood. EXPERIMENTAL APPROACH: CF bronchial epithelial cells were exposed to the corrector VX-809 (lumacaftor) and potentiator VX-770 (ivacaftor) individually or in combination. Functional expression of CFTR was assayed as the forskolin-stimulated short-circuit current (Isc ) across airway epithelial monolayers expressing F508del CFTR. KEY RESULTS: The potentiated Isc response during forskolin stimulation was increased sixfold after pretreatment with VX-809 alone and reached ~11% that measured across non-CF monolayers. VX-770 (100 nM) and genistein (50 muM) caused similar levels of potentiation, which were not additive and were abolished by the CFTR inhibitor CFTRinh -172. The unbound fraction of VX-770 in plasma was 0.13 +/- 0.04%, which together with previous measurements in patients given 250 mg p.o. twice daily, suggests a peak free plasma concentration of 1.5-8.5 nM. Chronic exposure to high VX-770 concentrations (>1 muM) inhibited functional correction by VX-809 but not in the presence of physiological protein levels (20-40 mg.mL(-1) ). Chronic exposure to a low concentration of VX-770 (100 nM) together with VX-809 (1 muM) also did not reduce the forskolin-stimulated Isc , relative to cells chronically exposed to VX-809 alone, provided it was assayed acutely using the same, clinically relevant concentration of potentiator. CONCLUSIONS AND IMPLICATIONS: Chronic exposure to clinically relevant concentrations of VX-770 did not reduce F508del CFTR function. Therapeutic benefit of VX-770 + VX-809 (Orkambi) is probably limited by the efficacy of VX-809 rather than by inhibition by VX-770.